Javelin Lung 101: This phase I/II trial is evaluating the safety and effictiveness of avelumab (an immunotherapy drug) when it is combined with one of two anti-cancer drugs (crizotinib or PF-06463922) for the treatment of Non Small Cell (NSC) Lung CancerA Phase 1b/2, Open-Label, Dose-Finding Study To Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Either Crizotinib Or PF-06463922 In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

Inclusion

• Inclusion Criteria
• Diagnosis of advanced or metastatic NSCLC. Group A must be ALK negative NSCLC and Group B must be ALK positive NSCLC
• Group A at least one prior regimen of therapy
• Group B any number of prior regimens.
• Mandatory tumor tissue available
• At least one measurable lesion
• ECOG Performance status 0 or 1
• Adequate bone marrow, renal, liver and pancreatic function
• Negative pregnancy test for females of childbearing potential
• Group B Phase 2: No prior systemic treatment for advanced or metastatic disease (adjuvant and/or neoadjuvant therapies are allowed if completed at least 6 months prior to study entry. No prior tyrosine kinase inhibitor therapy is allowed at any time prior to study entry)